Assessing Clinical Trial Experiences of Patients With Osteosarcoma


Study First Submitted Date 2022-09-06
Study First Posted Date 2022-09-10
Last Update Posted Date 2023-03-06
Start Month Year October 2023
Primary Completion Month Year October 2024
Verification Month Year September 2022
Verification Date 2022-09-30
Last Update Posted Date 2023-03-06


Sequence: 52009231
Name Osteosarcoma
Downcase Name osteosarcoma

Id Information

Sequence: 40032081
Id Source org_study_id
Id Value 83926159


Sequence: 79609480
Name osteosarcoma
Downcase Name osteosarcoma

Design Outcomes

Sequence: 176812409 Sequence: 176812410
Outcome Type primary Outcome Type primary
Measure Number of patients who decide to enroll in an osteosarcoma clinical trial Measure Rate of patients who remain in osteosarcoma clinical trial to trial completion
Time Frame 3 months Time Frame 12 months

Browse Conditions

Sequence: 192845684 Sequence: 192845678 Sequence: 192845679 Sequence: 192845680 Sequence: 192845681 Sequence: 192845682 Sequence: 192845683
Mesh Term Sarcoma Mesh Term Osteosarcoma Mesh Term Neoplasms, Bone Tissue Mesh Term Neoplasms, Connective Tissue Mesh Term Neoplasms, Connective and Soft Tissue Mesh Term Neoplasms by Histologic Type Mesh Term Neoplasms
Downcase Mesh Term sarcoma Downcase Mesh Term osteosarcoma Downcase Mesh Term neoplasms, bone tissue Downcase Mesh Term neoplasms, connective tissue Downcase Mesh Term neoplasms, connective and soft tissue Downcase Mesh Term neoplasms by histologic type Downcase Mesh Term neoplasms
Mesh Type mesh-ancestor Mesh Type mesh-list Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor


Sequence: 48167996
Agency Class INDUSTRY
Lead Or Collaborator lead
Name Power Life Sciences Inc.

Overall Officials

Sequence: 29192407
Role Study Director
Name Michael B Gill
Affiliation Power Life Sciences Inc.

Central Contacts

Sequence: 11972583
Contact Type primary
Name Michael B Gill
Phone 4159004227
Role Contact


Sequence: 30670427
Sampling Method Probability Sample
Gender All
Minimum Age 18 Years
Maximum Age N/A
Healthy Volunteers No
Population Osteosarcoma patients who are actively considering enrolling in an interventional clinical trial, but have not yet completed enrollment and randomization.
Criteria Inclusion Criteria: Patient has been diagnosed with osteosarcoma Patient has self-identified as planning to enroll in an interventional clinical trial Patient is a minimum of 18 years or older Exclusion Criteria: ECOG score of 4 Patient is pregnant Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form
Adult True
Child False
Older Adult True

Calculated Values

Sequence: 254295450
Registered In Calendar Year 2022
Were Results Reported False
Has Single Facility False
Minimum Age Num 18
Minimum Age Unit Years
Number Of Primary Outcomes To Measure 2


Sequence: 30417203
Observational Model Case-Crossover
Time Perspective Prospective

Provided Documents

Sequence: 2573325
Document Type Informed Consent Form
Has Protocol False
Has Icf True
Has Sap False
Document Date 2022-09-06

Responsible Parties

Sequence: 28783714
Responsible Party Type Sponsor

Study References

Sequence: 51897350 Sequence: 51897351 Sequence: 51897352
Pmid 18456784 Pmid 11925089 Pmid 19230551
Reference Type background Reference Type background Reference Type background
Citation Bielack S, Carrle D, Jost L; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii94-6. doi: 10.1093/annonc/mdn102. No abstract available. Citation Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, Malawer MM. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002 Mar 15;65(6):1123-32. Citation Burns L, Perisoglou M. Clinical trials in osteosarcoma treatment: patients' perspective through art. Recent Results Cancer Res. 2009;179:345-61. doi: 10.1007/978-3-540-77960-5_22.